FDA reports adverse effects of off-brand Ozempic amid ‘shortage’
The Food and Drug Administration is warning consumers not to use off-brand weight loss drugs containing semaglutide, the active ingredient in Ozempic and Wegovy. On Wednesday, officials warned about the dangers of drug compounding — which involves mixing or altering ingredients to create medication — after receiving reports of adverse effects after patients used compounded … Read more